Small-Molecule Env Conformation Modulation for HIV-1 ADCC Sensitization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HIV-1 treatment approaches face challenges due to mutation-derived resistance, drug toxicity, and compliance issues, limiting the effectiveness of antiretroviral therapies, while HIV-1 infected cells evade antibody-dependent cellular cytotoxicity (ADCC) through CD4 downregulation.

Innovation Solution

Development of small molecules that sensitize HIV-1 infected cells to ADCC by inducing CD4-bound Env conformation, exposing co-receptor binding site (CoRBS) epitopes, thereby enhancing ADCC-mediated killing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antiretroviral therapies targeting viral enzymes are used, then viral replication is inhibited, but mutation-derived resistance develops and drug toxicity increases

Engineering Contradiction:

Improveeffectiveness of HIV-1 treatmentVSAvoidmutation-derived resistance and drug toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses small molecule compounds as intermediaries that bind to the CD4 binding site on Env, inducing a conformational change that exposes CoRBS epitopes. This intermediary action sensitizes infected cells to ADCC without directly targeting viral enzymes, thereby avoiding the resistance and toxicity issues associated with traditional antiretroviral therapies.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/enzymatic inhibition approach of traditional antiretrovirals with a conformational sensing mechanism. Instead of blocking viral enzymes mechanically, the small molecules induce structural changes in Env that are detected by ADCC-mediating antibodies, substituting enzyme inhibition with conformational epitope exposure.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Object-affected harmful factors

If CD4 downregulation occurs to evade ADCC, then infected cells avoid antibody recognition, but the ability to sensitize cells to ADCC is reduced

Engineering Contradiction:

ImproveADCC-mediated killing of infected cellsVSAvoidvirus escape from antibody recognition

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The small molecule compounds perform preliminary action by pre-binding to the CD4 binding site and inducing the CD4-bound Env conformation before ADCC-mediating antibodies encounter the infected cells. This preliminary conformational change ensures that CoRBS epitopes are exposed and recognizable, countering the virus's escape mechanism of CD4 downregulation.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the conformational parameter of Env from the unbound state to the CD4-bound state through small molecule binding. This parameter change (structural conformation) exposes previously hidden CoRBS epitopes, allowing ADCC-mediating antibodies to recognize and kill infected cells even when CD4 levels are downregulated.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If small molecules induce CD4-bound Env conformation, then CoRBS epitopes are exposed and ADCC sensitivity increases, but molecular complexity of the treatment approach increases

Engineering Contradiction:

ImproveADCC sensitivity of infected cellsVSAvoidmolecular complexity of treatment compounds

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The small molecule compounds create a molecular copy or mimicry of the CD4 binding interaction. Rather than using the large, complex CD4 protein itself, the patent employs smaller molecular structures that replicate the essential binding and conformational-inducing properties of CD4, simplifying the treatment approach while maintaining effectiveness.

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The small molecules effectively sensitize HIV-1 infected cells to ADCC, potentially controlling transmission and disease progression by increasing the recognition and elimination of infected cells by ADCC-mediating antibodies.

Implementation Method 1

Conformational changes induced by Env:CD4 binding on the surface of HIV-1 infected cells leads to exposure of conserved CD4-induced (CD4i) epitopes on Env

Methodology Applied

Scientific EffectConformational change:

Implementation Method 2

exposure of conserved CD4-induced (CD4i) epitopes on Env that are recognized by ADCC-mediating antibodies (Abs)

Methodology Applied

Scientific EffectAntibody recognition and binding:

Implementation Method 3

Studies demonstrate that antibody-dependent cellular cytotoxicity (ADCC) plays an important role in controlling HIV-1 transmission and disease progression

Methodology Applied

Scientific EffectAntibody-dependent cellular cytotoxicity:

Data Source

PatentUS20250236593A1Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity

Publication Date: 2025.07.24 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

Compounds and methods of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 are provided. The compounds are of formula (I), (II), and (IA), wherein R1-R7, X, X′, Y, Y′, Z, and n are defined herein, and the methods comprises administering therapeutically effective amounts of these compounds to the human.